| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2017-05-22 | AC Immune (Switzerland) Essex Bio-Technology (China) | undisclosed novel protein therapeutic for the treatment of neurodegenerative diseases and neuroinflammation. | Neurodegenerative diseases, neuroinflammation. | research - R&D | Neurodegenerative diseases | Research agreement |
| 2017-05-18 | Teva Pharmaceutical Industries (Israel) Heptares Therapeutics (UK) | small-molecule calcitonin gene-related peptide (CGRP) antagonists | migraine | licensing - development - commercialisation | CNS diseases - Neurological diseases | Milestone |
| 2017-05-18 | Anagenesis Biotechnologies (France) Boehringer Ingelheim (Germany) | Paraxial Mesoderm Multipotent Cells (P2MCs) technology | chronic muscle diseases | R&D -research | Muscle disorders | Research agreement |
| 2017-05-16 | Noxxon Pharma (Germany) National Center for Tumor Diseases (NCT) in Heidelberg (Germany) | NOX-A12 (olaptesed pegol) and Keytruda® (pembrolizumab) | metastatic pancreatic cancer, metastatic colorectal cancer | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-16 | Oryzon Genomics (Spain) | nomination | Nomination | |||
| 2017-05-16 | Cambrex (USA - NJ) | construction of new premises | Technology - Services | Construction of new premises | ||
| 2017-05-16 | Boehringer Ingelheim (Germany) | commercial production site for biopharmaceuticals in China | opening of new premises | Technology - Services | Opening of new premises | |
| 2017-05-16 | Boehringer Ingelheim (Germany) Peking University (China) | collaboration | Cancer - Oncology - Cardiovascular diseases - CNS diseases - Immunological diseases - Metabolic diseases - Respiratory diseases | Collaboration agreement | ||
| 2017-05-16 | Lysogene (France) | chief operating officer | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2017-05-15 | Akebia Therapeutics (USA - MA) Vifor Pharma (Switzerland) Fresenius Medical Care (Germany) | vadadustat | anemia associated with chronic kidney disease | licensing | Kidney diseases - Renal diseases | Licensing agreement |
| 2017-05-15 | CytomX Therapeutics (USA - CA) | nomination | Cancer - Oncology | Nomination | ||
| 2017-05-15 | Takeda Pharmaceutical (Japan) Bushu Pharmaceuticals (Japan) Spera Pharma (Japan) | restructuring | Restructuring | |||
| 2017-05-15 | Bioverativ (USA - MA) | member of the board of directors | nomination | Rare diseases - Genetic diseases - Hematological diseases | Nomination | |
| 2017-05-12 | Newron (Italy) Zambon (Italy) | safinamide | Parkinson's disease | collaboration - licensing | Neurodegenerative diseases - CNS diseases | Milestone |
| 2017-05-12 | Emergent BioSolutions (USA - MD) | newly expanded Center for Innovation in Advanced Development and Manufacturing (CIADM) | opening of new premises | Infectious diseases | Opening of new premises | |
| 2017-05-12 | Molecular Partners (Switzerland) | chief executive officer | nomination | Nomination | ||
| 2017-05-10 | Chugai Pharmaceutical (Japan) JW Pharmaceutical (Republic of Korea) | emicizumab (ACE910 - anti-factor IXa x anti-factor X humanized bispecific antibody) | hemophilia A | licensing | Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2017-05-10 | Selvita (Poland) | research site in Poznan | opening of new premises | Opening of new premises | ||
| 2017-05-09 | Vaximm (Germany) Merck KGaA (Germany) Pfizer (USA - NY) | VXM01 and avelumab (MSB0010718C) | colorectal cancer, glioblastoma | clinical research | Cancer - Oncology | Clinical research agreement |
| 2017-05-09 | Kymab (UK) | nomination | Nomination |
